coinfection did (p = 0.0299). These findings suggested that coinfection with HPV 34 could prevent the tumor progression of invasive uterine cervical SCC with HPV 16 infection.
A recent study by us [5] has demonstrated a high prevalence of multiple HPV infection in Japanese patients with invasive uterine cervical cancer. The biological significance of multiple HPV infection remains elusive. Ho et al. [6] investigated the natural history of cervicovaginal HPVs and found an association between the presence of multiple HPV genotypes and the persistence (over 6 months) of infection. In contrast, other studies showed that persistent HPV infection was independent of coinfection with other HPV genotypes [7, 8] . The carcinogenic risk of multiple HPV infection is also controversial. Lee et al. [9] reported that patients infected with multiple HPV genotypes had a 31.8-fold higher risk of uterine cervical cancer compared to women without HPV infection, while those infected with a single HPV genotype had a 19.9-fold increased risk. On the other hand, Sasagawa et al. [10] reported that the odds ratio of multiple HPV infection was 24 for low-grade squamous intraepithelial lesions, 16 for high-grade squamous intraepithelial lesions, and 8.3 for SCC of the uterine cervix. This discrepancy could reflect the diverse interaction among HPV genotypes.
Tumor progression is evaluated clinically by local growth, metastasis to the regional lymph nodes, and distant metastasis. According to the International Federation of Gynecology and Obstetrics (FIGO) classification, invasive uterine cervical cancer which can be diagnosed only by microscopy is classified as stage Ia. Clinically visible lesions limited to the uterine cervix or preclinical cancers greater than stage Ia are classified as stage Ib. Cervical cancers invading beyond the uterus are classified as stage II or higher. In the present study, the correlation of multiple HPV infection with the FIGO stage (Ib or >Ib) and lymph node metastasis (negative or positive) was examined concerning clinically visible, not microscopic, invasive uterine cervical SCC.
Materials and Methods

Clinical Samples
This study was conducted with permission of the Medical Ethics Committee of the Hokkaido University Graduate School of Medicine. A total of 42 cases of invasive uterine cervical SCCs were obtained from the archives of fresh-frozen tissues between the period of 1999 and 2004 at the Department of Gynecology of the Hokkaido University, Sapporo, Japan. Written informed consent was obtained from all patients. Tissues (5 mm 3 ) were obtained from the inside of the tumors to avoid contamination of extrinsic HPVs. The patients' age ranged from 20 to 71 years with an average of 47.6 years ( table 1 ). A gynecologic oncologist performed pelvic examination and staging of the carcinoma according to the FIGO classification. The status of lymph node metastasis of 36 patients who underwent radical hysterectomy was recorded.
HPV Genotyping
Genomic DNA was extracted from fresh-frozen tissues of 42 cases of invasive uterine cervical SCCs using the PureGene DNA isolation kit (Qiagen, Tokyo, Japan) and stored at -20 ° C until use. HPV genotyping was performed using the HPV array as described [5] . The array was designed to detect 13 17, 20, 21 , and 47). The specificity and sensitivity of this array were described elsewhere [5] .
Statistical Analysis
The correlation between the status of HPV infection and the clinical factors, including the FIGO stage (Ib or >Ib) and lymph node metastasis (negative or positive), was examined. For this analysis, Fisher's exact test was employed. Next, the correlation between the HPV infection status and clinicopathological factors, including the FIGO stage (Ib or >Ib), lymph node metastasis (negative or positive), differentiation of carcinoma cells (keratinizing or nonkeratinizing), counts of mitotic figures [0-5/10 high-power fields of view (HPF) or >5/10 HPF], and lymphatic and vascular invasions (negative or positive), was examined. For this purpose, multivariate analysis was performed. In both analyses, p < 0.05 were considered to be significant. Figure 1 shows the frequency of HPV genotypes detected in invasive SCC of the uterine cervix. Among the high-risk genotypes, HPV 16, 18, 31, 33, 35, 52, and 58 were detected. The most prevalent genotype was HPV 16 (37/42, 88.1%), followed by HPV 52 (17/42, 40.5%) and 
Results
Detection of HPV Genotypes
Effects of Multiple HPV Infection on Tumor Progression of Invasive Uterine Cervical SCC
HPV 16 is the most predominant genotype that contributes to the development of SCC of the uterine cervix [1] . Correspondingly, HPV 16 was detected most frequently in this study. To determine the significance of multiple HPV infection in tumor progression, the effects of the coinfection with genotypes other than HPV 16 on the FIGO stage (Ib or >Ib) and lymph node metastasis (negative or positive) of invasive SCC with HPV 16 infection were examined ( table 3 ) . Prior to conduction of this analysis, we expected that coinfection with some genotypes would promote the tumor progression of SCC with HPV 16 infection. However, the coinfection with most genotypes had no influence on either the FIGO stage or lymph node metastasis. Interestingly, contrary to our expectation, the FIGO stage of patients coinfected with HPV 16 and HPV 34 was significantly lower than that of those without HPV 34 coinfection (p = 0.0038). Moreover, no patient coinfected with HPV 16 and HPV 34 manifested lymph node metastasis, whereas about half of the patient population without HPV 34 coinfection experienced lymph node metastasis (p = 0.0299).
To verify this relation, a multivariate analysis was conducted between the HPV infection status (HPV 16 with HPV 34 or HPV 16 without HPV 34) and clinicopathological factors, including the FIGO stage (Ib or >Ib), lymph node metastasis (negative or positive), differentiation of carcinoma cells (keratinizing or nonkeratinizing), counts of mitotic figures (0-5/10 HPF or >5/10 HPF), and lymphatic and vascular invasions (negative or positive). As a result, the FIGO stage and the state of lymph node metastasis were significantly correlated to the HPV infection status (p = 0.0113 and p = 0.0167, respectively; table 4 ). The next correlative factor was the state of lymphatic invasion, though the correlation did not reach the statistically significant level.
Discussion
The E6 and E7 of high-risk HPVs are critically involved in the carcinogenesis of uterine cervical cancer [11] . HPV E6 has 2 zinc-finger loops that can bind with host proteins, one of which is the E6-associated protein (E6AP) and the other is the tumor-suppressive cell-cycle regulator, p53 [12] . The E6AP is a ubiquitin ligase that can yield polyubiquitination of the related proteins [13] . High-risk HPV E6 can bind with E6AP and p53, and then E6AP yields polyubiquitination of p53 [14] . The polyubiquitinated p53 is subsequently degraded by proteasome resulting in an acceleration of the cell cycle [15, 16] . On the other hand, high-risk HPV E7 can bind with retinoblastoma protein (pRB) that holds and inactivates the cell-cycle promoter, E2F1 [17] . The pRB bound to E7 is phosphorylated, and then E2F1 is released resulting in acceleration of the cell cycle. In addition, the high-risk E7 is suggested to act as a mitotic mutator, which can increase the chance of errors during each round of cell division [18] .
In order to determine the mechanism of how HPV 34 prevents the progression of invasive SCC with HPV 16 infection, the amino acid sequences of E6 and E7 regions were compared among the high-risk genotypes HPV 16, 18, 31, 33, 35, 52, and 58, and the low-risk genotypes HPV 6, 11, and 34. The E6 sequences of all genotypes include 2 zinc-finger loops ( fig. 2 , highlighted in green) . There are characteristic differences in the E6AP-binding site and the p53-binding site between the high-risk genotypes and the low-risk genotypes, including HPV 6 and HPV 11 (highlighted in light blue in the E6AP-binding site and in yellow in the p53-binding site). These divergences could reflect the difference in the carcinogenic risk of HPVs. Interestingly, although the critical p53-binding site sequences of HPV 34 are identical to the high-risk genotypes (highlighted in yellow), the E6AP-binding site sequences are different (highlighted in light blue). These findings suggest that HPV 34 E6 can bind to p53 but may not bind to E6AP, or if it can bind to E6AP, the binding affinity may be weaker than that of high-risk HPVs. Accordingly, p53 bound to HPV 34 E6 is possibly difficult to be polyubiquitinated by E6AP compared with that bound to E6 of high-risk HPVs resulting in an escape from degradation by proteasome. Regarding the other low-risk genotypes, including HPV 6 and HPV 11, such a protective potential of p53 is not likely because the critical p53-binding sequences (highlighted in yellow) are different from those of high-risk genotypes. The present study demonstrated the possibility that coinfection with HPV 34 with HPV 16 infection prevented the tumor progression of invasive uterine cervical SCC. The FIGO stage and the state of lymph node metastasis were significantly correlated to the HPV infection status. The state of lymphatic invasion also tended to correspond with the HPV infection status. These findings supported our conclusion that HPV 16-positive uterine cervical SCC with coinfection with HPV 34 was not likely to invade lymphatic vessels compared to that without coinfection with HPV 34, which resulted in the lower FIGO stage. Although further study with a larger number of cases and investigation into the molecular mechanism in which HPV 34 competes with HPV 16 for p53 binding are needed, the results of this study suggest that reagents which compete with high-risk HPVs for p53 binding could be novel candidates for the treatment of invasive SCC of the uterine cervix. The characteristic differences between high-risk genotypes and low-risk genotypes, including HPV 6 and HPV 11, are highlighted in yellow.
